Patents by Inventor Lars Kyhn Rasmussen

Lars Kyhn Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines
    Patent number: 11851425
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: December 26, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
    Patent number: 11634416
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 25, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
    Patent number: 11535611
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 27, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11491140
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 8, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 11472810
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: October 18, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20220220095
    Abstract: The present invention provides N-(heteroaryl)methyl)-1-tosyl-1H-pyrazole-3-carboxamide derivatives of the structure Formula (I), which activate the Kv3 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and to the compounds and pharmaceutical compositions thereof for use in methods of medical treatment of disorders responsive to the activation of Kv3 potassium channels, such as e.g. neurological or psychiatric disorders for example epilepsy, schizophrenia, cognitive impairment associated with schizophrenia (CIAS), autism spectrum disorder, bipolar disorder, ADHD, anxiety-related disorders, depression, cognitive dysfunction, Alzheimer's disease, Fragile X syndrome, chronic pain, hearing loss, sleep and circadian disorders, and sleep disruption. Exemplary compounds are e.g.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 14, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
    Publication number: 20220204489
    Abstract: The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and use of the compounds to treat disorders responsive to the activation of Kv3 potassium channels.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors
    Patent number: 11104680
    Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: August 31, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
  • IMIDAZOPYRAZINONES AS PDE1 INHIBITORS
    Publication number: 20210238182
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: October 26, 2020
    Publication date: August 5, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11026923
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: June 8, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11026924
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: June 8, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
    Patent number: 10912773
    Abstract: The present invention provides combination treatments comprising compounds of Formula (I): that are PDE1 enzyme inhibitors, and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 9, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Combinations comprising substituted imidazo[1,5-?]pyrazinones as PDE1 inhibitors
    Patent number: 10905688
    Abstract: The present invention provides combination treatments comprising compounds of Formula (I): that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 2, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
    Publication number: 20210023056
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
    Publication number: 20210015794
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS
    Publication number: 20210009571
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 14, 2021
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgârd, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
    Publication number: 20200385372
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
    Type: Application
    Filed: December 12, 2018
    Publication date: December 10, 2020
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgard, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
    Publication number: 20200385381
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.
    Type: Application
    Filed: December 12, 2018
    Publication date: December 10, 2020
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 10858362
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: December 8, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
    Publication number: 20200375950
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders,
    Type: Application
    Filed: August 21, 2020
    Publication date: December 3, 2020
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson